Yuan Xin, Liang Bei-Bei, Wang Rui, Liu You-Ning, Sun Chun-Guang, Cai Yun, Yu Xu-Hong, Bai Nan, Zhao Tie-Mei, Cui Jun-Chang, Chen Liang-An
Department of Respiratory Diseases, General Hospital of Chinese People’s Liberation Army, Beijing, China.
J Chemother. 2012 Oct;24(5):257-67. doi: 10.1179/1973947812Y.0000000028.
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality throughout the world. To investigate whether moxifloxacin monotherapy is associated with better clinical outcomes than other antibiotics recommended for CAP among adults with mild-to-moderate or severe CAP, we performed a meta-analysis. MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched for randomized control trials (RCTs). The efficacy and safety of moxifloxacin were compared with other antimicrobial agents used to treat CAP. Fourteen RCTs, consisting of 6923 total patients, were included in the meta-analysis. No difference was found regarding the incidence of adverse events and mortality between moxifloxacin and the compared regimens. We found that moxifloxacin is as effective and well-tolerated as other recommended antibiotics for the treatment of CAP and possesses a better pathogen eradication rate than beta-lactam-based therapy.
社区获得性肺炎（CAP）是全球发病和死亡的主要原因。为了研究在患有轻至中度或重度CAP的成年人中，莫西沙星单药治疗是否比其他推荐用于CAP的抗生素具有更好的临床疗效，我们进行了一项荟萃分析。检索了MEDLINE、EMBASE、科学引文索引和考科蓝图书馆以查找随机对照试验（RCT）。将莫西沙星的疗效和安全性与其他用于治疗CAP的抗菌药物进行比较。荟萃分析纳入了14项RCT，共计6923例患者。莫西沙星与对照方案在不良事件发生率和死亡率方面未发现差异。我们发现，莫西沙星在治疗CAP方面与其他推荐抗生素一样有效且耐受性良好，并且比基于β-内酰胺类的治疗具有更好的病原体根除率。
